

# Rakesh Jalali

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6450589/publications.pdf>

Version: 2024-02-01

84  
papers

1,392  
citations

331670

21  
h-index

377865

34  
g-index

108  
all docs

108  
docs citations

108  
times ranked

1958  
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors Influencing Neurocognitive Outcomes in Young Patients With Benign and Low-Grade Brain Tumors Treated With Stereotactic Conformal Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 974-979.	0.8	134
2	Prospective Evaluation of Radiotherapy With Concurrent and Adjuvant Temozolomide in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 113-118.	0.8	90
3	Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. <i>Neuro-Oncology</i> , 2013, 15, 1644-1651.	1.2	73
4	Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. <i>Journal of Neuro-Oncology</i> , 2009, 95, 413-419.	2.9	61
5	Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors. <i>JAMA Oncology</i> , 2017, 3, 1368.	7.1	59
6	Optimization of stereotactically-guided conformal treatment planning of sellar and parasellar tumors, based on normal brain dose volume histograms. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 507-513.	0.8	57
7	Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients. <i>Neuro-Oncology</i> , 2019, 21, 115-124.	1.2	49
8	Indian data on central nervous tumors: A summary of published work. <i>South Asian Journal of Cancer</i> , 2016, 05, 147-153.	0.6	49
9	Factors influencing activities of daily living using FIM and FAM scoring system before starting adjuvant treatment in patients with brain tumors: results from a prospective study. <i>Journal of Neuro-Oncology</i> , 2009, 94, 103-110.	2.9	41
10	Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India. <i>Journal of Neuro-Oncology</i> , 2008, 87, 111-114.	2.9	40
11	Techniques of tumour bed boost irradiation in breast conserving therapy: Current evidence and suggested guidelines. <i>Acta Oncologica</i> , 2007, 46, 879-892.	1.8	39
12	Restoration of miR-30a expression inhibits growth, tumorigenicity of medulloblastoma cells accompanied by autophagy inhibition. <i>Biochemical and Biophysical Research Communications</i> , 2017, 491, 946-952.	2.1	38
13	Hippocampal radiotherapy dose constraints for predicting long-term neurocognitive outcomes: mature data from a prospective trial in young patients with brain tumors. <i>Neuro-Oncology</i> , 2020, 22, 1677-1685.	1.2	37
14	MiR-148a, a microRNA upregulated in the WNT subgroup tumors, inhibits invasion and tumorigenic potential of medulloblastoma cells by targeting Neuropilin 1. <i>Oncoscience</i> , 2015, 2, 334-348.	2.2	32
15	Breast cancer in a tertiary cancer center in India - An audit, with outcome analysis. <i>Indian Journal of Cancer</i> , 2018, 55, 16.	0.2	29
16	Intracranial germ cell tumors: a multi-institutional experience from three tertiary care centers in India. <i>Child's Nervous System</i> , 2016, 32, 2173-2180.	1.1	27
17	Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma. <i>Journal of Neuro-Oncology</i> , 2018, 136, 343-350.	2.9	26
18	Clinical outcomes of prospectively treated 140 women with early stage breast cancer using accelerated partial breast irradiation with 3 dimensional computerized tomography based brachytherapy. <i>Radiotherapy and Oncology</i> , 2015, 115, 349-354.	0.6	24

#	ARTICLE	IF	CITATIONS
19	Factors influencing quality of life in adult patients with primary brain tumors. <i>Neuro-Oncology</i> , 2012, 14, iv8-iv16.	1.2	23
20	Can Multiparametric MRI and FDG-PET Predict Outcome in Diffuse Brainstem Glioma? A Report from a Prospective Phase-II Study. <i>Pediatric Neurosurgery</i> , 2013, 49, 274-281.	0.7	23
21	IAEA randomised trial of optimal single dose radiotherapy in the treatment of painful bone metastases. <i>Radiotherapy and Oncology</i> , 2015, 116, 10-14.	0.6	22
22	Long-term Survivors of Childhood Brain Tumors: Impact on General Health and Quality of Life. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 99.	4.2	22
23	Suprasellar ganglioglioma with unusual diffuse involvement of the entire optico-chiasmal hypothalamic pathway. <i>Journal of Cancer Research and Therapeutics</i> , 2008, 4, 140.	0.9	22
24	High precision conformal radiotherapy employing conservative margins in childhood benign and low-grade brain tumours. <i>Radiotherapy and Oncology</i> , 2005, 74, 37-44.	0.6	21
25	Prospective assessment of activities of daily living using Modified Barthel's Index in children and young adults with low-grade gliomas treated with stereotactic conformal radiotherapy. <i>Journal of Neuro-Oncology</i> , 2008, 90, 321-328.	2.9	19
26	Encouraging efficacy of modern conformal fractionated radiotherapy in patients with uncured Cushing's disease. <i>Pituitary</i> , 2014, 17, 60-67.	2.9	18
27	International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology. <i>Neuro-Oncology Practice</i> , 2015, 2, 62-69.	1.6	18
28	Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma. <i>CNS Oncology</i> , 2019, 8, CNS46.	3.0	18
29	Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups. <i>Child's Nervous System</i> , 2019, 35, 1525-1536.	1.1	17
30	Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas. <i>Acta Neuropathologica Communications</i> , 2019, 7, 52.	5.2	17
31	Reverse swing, phase 1 study of repurposing mebendazole in recurrent high-grade glioma. <i>Cancer Medicine</i> , 2020, 9, 4676-4685.	2.8	16
32	Prospective evaluation of concomitant tumour bed boost with whole breast irradiation in patients with locally advanced breast cancer undergoing breast-conserving therapy. <i>Breast</i> , 2008, 17, 64-70.	2.2	13
33	Cabergoline may act as a radioprotective agent in Cushing's disease. <i>Clinical Endocrinology</i> , 2020, 92, 55-62.	2.4	12
34	Omission of Upfront Craniospinal Irradiation in Patients with Low-Risk WNT-Pathway Medulloblastoma Is Associated with Unacceptably High Risk of Neuraxial Failure. <i>Clinical Cancer Research</i> , 2022, 28, 4180-4185.	7.0	12
35	MiR-592 activates the mTOR kinase, ERK1/ERK2 kinase signaling and imparts neuronal differentiation signature characteristic of Group 4 medulloblastoma. <i>Human Molecular Genetics</i> , 2021, 30, 2416-2428.	2.9	11
36	Neuropsychological status in children and young adults with benign and low-grade brain tumors treated prospectively with focal stereotactic conformal radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S14-S19.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Global Cancer Clinical Trialsâ€” Cooperation Between Investigators in High-Income Countries and Low- and Middle-Income Countries. <i>JAMA Oncology</i> , 2018, 4, 765.	7.1	10
38	Palliative care and quality of life in neuro-oncology. <i>F1000prime Reports</i> , 2014, 6, 71.	5.9	10
39	MGMT gene promoter methylation and its correlation with clinicopathological parameters in glioblastomas. <i>Neurology India</i> , 2018, 66, 1106.	0.4	10
40	Transperineal Low-Dose Rate Iridium-192 Interstitial Brachytherapy in Cervical Carcinoma Stage IIB. <i>Strahlentherapie Und Onkologie</i> , 2001, 177, 517-524.	2.0	9
41	Translation and pilot validation of Hindi translation of assessing quality of life in patients with primary brain tumours using EORTC brain module (BN-20). <i>Journal of Cancer Research and Therapeutics</i> , 2006, 2, 166.	0.9	9
42	Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?. <i>Clinical Neurology and Neurosurgery</i> , 2015, 135, 46-53.	1.4	8
43	Impact of timing of radiation therapy on outcomes in atypical meningioma: A clinical audit. <i>Practical Radiation Oncology</i> , 2018, 8, e275-e284.	2.1	8
44	Clinical approach to re-irradiation for recurrent diffuse intrinsic pontine glioma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 762-768.	1.3	8
45	Downregulation of ARID1B, a tumor suppressor in the WNT subgroup medulloblastoma, activates multiple oncogenic signaling pathways. <i>Human Molecular Genetics</i> , 2021, 30, 1721-1733.	2.9	8
46	Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy. <i>CNS Oncology</i> , 2018, 7, CNS14.	3.0	7
47	Histological spectrum of oligodendroglial tumors: Only a subset shows 1p/19q codeletion. <i>Neurology India</i> , 2017, 65, 113.	0.4	7
48	Clinical outcome and molecular characterization of pediatric glioblastoma treated with postoperative radiotherapy with concurrent and adjuvant temozolomide: a single institutional study of 66 children. <i>Neuro-Oncology Practice</i> , 2016, 3, 39-47.	1.6	6
49	Impact of adjuvant systemic chemotherapy on wound healing and cosmetic outcome in 224 women treated with accelerated partial breast irradiation using interstitial brachytherapy. <i>Brachytherapy</i> , 2017, 16, 935-942.	0.5	6
50	Primary pineal tumors â€” Unraveling histological challenges and certain clinical myths. <i>Neurology India</i> , 2019, 67, 491.	0.4	6
51	Micromultileaf collimator-based stereotactic radiosurgery for selected arteriovenous malformations: Technique and preliminary experience. <i>Journal of Cancer Research and Therapeutics</i> , 2009, 5, 186.	0.9	6
52	A comparison of long-term clinical outcomes of accelerated partial breast irradiation using interstitial brachytherapy as per GEC-ESTRO, ASTRO, updated ASTRO, and ABS guidelines. <i>Brachytherapy</i> , 2020, 19, 337-347.	0.5	5
53	Clinical Audit of Survival Outcomes and Prognostic Factors in Adolescents and Adults with Medulloblastoma. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 68-77.	1.3	5
54	Demographic profile, clinicopathological spectrum, and treatment outcomes of primary central nervous system tumors: Retrospective audit from an academic neuro-oncology unit. <i>Indian Journal of Cancer</i> , 2017, 54, 594.	0.2	5

#	ARTICLE	IF	CITATIONS
55	Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy. <i>BMJ Case Reports</i> , 2021, 14, e240296.	0.5	4
56	A randomized trial of stereotactic versus conventional radiotherapy in young patients with low-grade brain tumors: occupational therapy-based neurocognitive data. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa130.	0.7	4
57	Curability of cancer by radiotherapy and chemotherapy, including in neuraxial neoplasms. <i>Neurology India</i> , 2009, 57, 13.	0.4	3
58	Distinct demographic profile and molecular markers of primary CNS tumor in 1873 adolescent and young adult patient population. <i>Child's Nervous System</i> , 2018, 34, 1489-1495.	1.1	3
59	Dose-Constraint Model to Predict Neuroendocrine Dysfunction in Young Patients With Brain Tumors: Data From a Prospective Study. <i>Practical Radiation Oncology</i> , 2019, 9, e362-e371.	2.1	3
60	Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma. <i>Ecancermedalscience</i> , 2021, 15, 1166.	1.1	3
61	Is there a need to regulate health care advertisement for lay public?. <i>Journal of Cancer Research and Therapeutics</i> , 2010, 6, 131.	0.9	2
62	Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center. <i>Neuro-Oncology Practice</i> , 2019, 6, 479-483.	1.6	2
63	TERT Promoter Mutation in Adult Glioblastomas: It's Correlation with Other Relevant Molecular Markers. <i>Neurology India</i> , 2021, 69, 126.	0.4	2
64	Hyperfractionated craniospinal re-irradiation for recurrent/progressive disseminated medulloblastoma using image-guided radiotherapy: leveraging radiobiology with technology. <i>Journal of Radiation Oncology</i> , 2012, 1, 87-92.	0.7	1
65	Neuro-Oncology Practice: Consolidating A Good Beginning. <i>Neuro-Oncology Practice</i> , 2014, 1, 31-32.	1.6	1
66	Prospective longitudinal assessment of sensorineural hearing loss with hyperfractionated radiation therapy alone in patients with average-risk medulloblastoma. <i>Neuro-Oncology Practice</i> , 2014, 1, 86-93.	1.6	1
67	Neuro-Oncology Practice: old challenges, new insights. <i>Neuro-Oncology Practice</i> , 2016, 3, 69-70.	1.6	1
68	Helical tomotherapy-based craniospinal irradiation: mature outcomes of a prospective feasibility study. <i>Journal of Radiation Oncology</i> , 2016, 5, 221-230.	0.7	1
69	Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. <i>World Neurosurgery</i> , 2021, 154, e176-e184.	1.3	1
70	Prospective assessment of neurocognitive outcomes in children and young adults with progressive/residual benign and low-grade brain tumors treated with high-precision conformal or conventional radiotherapy: Results of a randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2035-2035.	1.6	1
71	Long term results of a prospective study of internal mammary chain (IMC) brachytherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, e12061-e12061.	1.6	1
72	SHADOW study: Comparison of conventional clinical follow-up with clinician led video follow-up in newly diagnosed patients with intermediate and high grade glioma receiving adjuvant temozolomide therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2024-2024.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Prognostic impact of semantic MRI features on survival outcomes in molecularly subtyped medulloblastoma. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 291.	2.0	1
74	Diversity of challenges in neuro-oncology: basic realities and new insights. <i>Neuro-Oncology Practice</i> , 2015, 2, 55-56.	1.6	0
75	Commentary on 19th annual scientific meeting of the Society for Neuro-Oncology. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 63.	0.2	0
76	Patient survivorship and caregivers'™ needs in neuro-oncology practice: burden and novel interventions. <i>Neuro-Oncology Practice</i> , 2017, 4, 75-76.	1.6	0
77	LGG-08. PILOCYTIC ASTROCYTOMAS, EXHIBIT DIFFERENTIAL AGE-BASED PATTERNS OF BRAFV600E AND BRAF GENE FUSIONS ACROSS DIFFERENT LOCATIONS. <i>Neuro-Oncology</i> , 2018, 20, i105-i106.	1.2	0
78	DEV-11. OUTCOMES OF MALIGNANT BRAIN TUMORS IN YOUNG CHILDREN TREATED WITH CHEMOTHERAPY AND DELAYED RADIOTHERAPY IN A RESOURCE LIMITED SETTING. <i>Neuro-Oncology</i> , 2018, 20, i47-i47.	1.2	0
79	MBRS-41. DIFFERENTIAL microRNA EXPRESSION IN THE MOLECULAR SUBGROUPS OF MEDULLOBLASTOMAS: ROLE IN TUMOR BIOLOGY AND CLINICAL CHARACTERISTICS. <i>Neuro-Oncology</i> , 2018, 20, i137-i137.	1.2	0
80	EPEN-19. SUPRATENTORIAL EPENDYMOMAS - L1CAM EXPRESSION AND RELA FUSION, THEIR CORRELATION WITH CLINICOPATHOLOGICAL FEATURES. <i>Neuro-Oncology</i> , 2018, 20, i77-i77.	1.2	0
81	A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. <i>Neuro-Oncology Practice</i> , 2019, 6, 305-310.	1.6	0
82	Heterogeneous spectrum of childhood and adult SHH medulloblastoma: Clinical, radiogenomic features, patterns of failure and survival.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2063-2063.	1.6	0
83	Pediatric Glioma. <i>Pediatric Oncology</i> , 2018, , 171-202.	0.5	0
84	Pilot testing and vernacular translation of a questionnaire for assessment of satisfaction in patients on radiotherapy in India. <i>Indian Journal of Cancer</i> , 2021, 58, 573.	0.2	0